Stealth BioTherapeutics Corp (MITO) Stock Analysis
DELISTED 2022
What happened to Stealth BioTherapeutics Corp (MITO) stock?
Stealth BioTherapeutics Corp (MITO) no longer trades on public markets. It was delisted in November 2022. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Stealth BioTherapeutics Corp (MITO) trades at $0.32. Stealth BioTherapeutics Corp is a clinical-stage biotechnology company focused on developing therapies for mitochondrial dysfunction. Their lead product candidate, Elamipretide, is undergoing clinical trials for various diseases. Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for MITO: MITO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MITO against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
MITO: 1/2 scored disciplines lean bullish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Stealth BioTherapeutics Corp (MITO) Healthcare & Pipeline Overview
Stealth BioTherapeutics Corp, a clinical-stage biotechnology firm, specializes in mitochondrial dysfunction therapies, with Elamipretide as its lead candidate. Currently, Elamipretide is in Phase 3 trials for Barth syndrome and Replisome myopathies, positioning the company within the competitive biotechnology landscape focused on rare diseases.
What Is the Investment Thesis for MITO?
Stealth BioTherapeutics Corp presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's lead drug candidate, Elamipretide, is currently in Phase 3 clinical trials, representing a significant potential catalyst for valuation. Successful trial outcomes and subsequent regulatory approvals could drive substantial revenue growth. However, the company's negative P/E ratio of -0.28 reflects its current lack of profitability and reliance on future drug approvals. The company's success hinges on the clinical trial results and regulatory approval of Elamipretide and other pipeline candidates, making it a speculative investment.
Based on FMP financials and quantitative analysis
MITO Key Highlights
Elamipretide is in Phase 3 clinical trials for Barth syndrome, indicating potential near-term revenue if approved.
- Elamipretide is in Phase 2/3 clinical trials for Duchenne cardiomyopathy, addressing a significant unmet need.
- The company has a negative P/E ratio of -0.28, reflecting its current lack of profitability.
- Stealth BioTherapeutics has a diverse pipeline including SBT-20, SBT-550, and SBT-272 targeting various diseases.
- The company is based in George Town, Cayman Islands, which may have tax implications for some investors.
Who Are MITO's Competitors?
MITO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ANPC AnPac Bio-Medical Science Co., Ltd. | $4.30 | -3.15% | $27.0M | 50 |
| ELEV ELEV | $0.36 | -2.12% | $21.6M | 47 |
| FRLN Freeline Therapeutics Holdings plc | $6.49 | +0.15% | $28.3M | 44 |
| GMTX Gemini Therapeutics, Inc. | $1.35 | +0.00% | $25.5M | 46 |
| LSB LakeShore Biopharma Co., Ltd | $0.63 | +0.00% | $25.8M | 46 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MITO's Key Strengths?
Clinical-stage pipeline with multiple indications.
- Focus on mitochondrial dysfunction, a specialized area.
- Lead product candidate in Phase 3 trials.
- Experienced management team.
What Are MITO's Weaknesses?
Negative P/E ratio indicates lack of profitability.
- Reliance on successful clinical trial outcomes.
- High cash burn rate.
- Limited commercialization experience.
What Could Drive MITO Stock Higher?
Phase 3 clinical trial results for Elamipretide in Barth syndrome expected in late 2026.
- Potential FDA approval of Elamipretide for Barth syndrome in 2027.
- Continued development of SBT-20 for complications of diabetes and neurodegenerative diseases.
- Advancement of Elamipretide for Duchenne cardiomyopathy through Phase 2/3 clinical trials.
What Are the Key Risks for MITO?
Clinical trial failures for Elamipretide or other pipeline candidates.
- Regulatory delays or rejection of marketing applications.
- Competition from other biotechnology companies developing therapies for similar indications.
- High cash burn rate and need for additional financing.
- Patent expirations on key drug candidates.
What Are the Growth Opportunities for MITO?
- Successful completion and FDA approval of Elamipretide for Barth syndrome represents a significant growth opportunity. Barth syndrome is a rare genetic disorder, and an approved therapy would grant Stealth BioTherapeutics a first-mover advantage in a market with limited treatment options. The market size is constrained by the rarity of the disease, but pricing power could be substantial, potentially driving significant revenue within the next 2-3 years upon approval.
- Advancement of Elamipretide for Duchenne cardiomyopathy to market offers another substantial growth avenue. Duchenne muscular dystrophy affects a larger patient population, and successful clinical outcomes could lead to a broader market opportunity. This indication is in Phase 2/3 trials, suggesting a potential market entry within the next 3-5 years if trials are successful and regulatory approval is obtained.
- Development and commercialization of SBT-20 for treating complications of diabetes and neurodegenerative diseases presents a long-term growth opportunity. These indications represent large and growing markets, but development is in earlier stages. Success in these areas could significantly expand Stealth BioTherapeutics' revenue base over the long term, potentially in 5-7 years.
- Expansion of the pipeline with SBT-550 for rare neurological indications could provide additional growth. Rare neurological diseases often have limited treatment options, creating opportunities for innovative therapies. This growth driver is dependent on successful preclinical and clinical development, with potential market entry in 5-7 years.
- Strategic partnerships and collaborations with larger pharmaceutical companies could accelerate the development and commercialization of Stealth BioTherapeutics' pipeline. Collaborations can provide access to funding, expertise, and distribution networks, enhancing the company's growth prospects. These partnerships could materialize at any time, providing an immediate boost to the company's resources and capabilities.
What Are MITO's Competitive Advantages?
- Patented drug candidates provide exclusivity.
- Focus on rare diseases creates niche market opportunities.
- Clinical-stage pipeline represents a barrier to entry.
- Expertise in mitochondrial dysfunction therapies.
What Does MITO Do?
Stealth BioTherapeutics Corp, founded in 2006 and based in George Town, Cayman Islands, is a clinical-stage biotechnology company dedicated to discovering, developing, and commercializing therapies for diseases involving mitochondrial dysfunction. The company's primary focus is on Elamipretide, a drug candidate currently in Phase 3 clinical trials for Barth syndrome and Replisome myopathies, as well as Phase 2/3 trials for Duchenne cardiomyopathy. Additionally, Elamipretide is undergoing Phase 2a trials for Friedreich's ataxia and Phase 2 trials for both dry age-related macular degeneration and Leber's hereditary optic neuropathy. Beyond Elamipretide, Stealth BioTherapeutics is developing a pipeline of product candidates, including SBT-20 for treating complications of diabetes, renal diseases, ocular diseases, and neurodegenerative conditions such as Parkinson's, Alzheimer's, Huntington's, and ALS diseases. SBT-550 is being developed for rare neurological indications, and SBT-272, a peptidomimetic, aims to stabilize mitochondrial function under oxidative stress. The company's research and development efforts are centered on addressing unmet medical needs in diseases characterized by mitochondrial dysfunction.
What Products and Services Does MITO Offer?
- Develop therapies for diseases involving mitochondrial dysfunction.
- Focus on clinical-stage drug development.
- Lead product candidate is Elamipretide.
- Conduct Phase 3 clinical trials for Barth syndrome and Replisome myopathies.
- Conduct Phase 2/3 clinical trials for Duchenne cardiomyopathy.
- Develop SBT-20 for complications of diabetes and neurodegenerative diseases.
- Develop SBT-550 for rare neurological indications.
- Develop SBT-272 to stabilize mitochondrial function.
How Does MITO Make Money?
- Develop and patent novel therapies for mitochondrial dysfunction.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from agencies like the FDA.
- Commercialize approved therapies directly or through partnerships.
What Industry Does MITO Operate In?
Stealth BioTherapeutics Corp operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The company focuses on mitochondrial dysfunction, a niche area within the broader biotechnology landscape. Competitors like AnaptysBio (ANPC), ElevateBio (ELEV), Freeline Therapeutics (FRLN), Gamida Cell (GMTX), and LSB Industries (LSB) operate in different therapeutic areas, but all face similar challenges in drug development and commercialization. The biotechnology industry is expected to continue growing, driven by advancements in genomics, personalized medicine, and increasing demand for innovative therapies.
Who Are MITO's Key Customers?
- Patients with Barth syndrome.
- Patients with Duchenne cardiomyopathy.
- Patients with Friedreich's ataxia.
- Patients with dry age-related macular degeneration.
- Patients with Leber's hereditary optic neuropathy.
- Patients with Replisome myopathies.
Company Profile
Stealth BioTherapeutics Corp operates in the Biotechnology industry within the Healthcare sector. It is headquartered in George Town, KY. The company is led by CEO Irene P. McCarthy. MITO has traded publicly since 2019.
Key Financial Metrics
Return on equity for Stealth BioTherapeutics Corp stands at 193.2%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 4.58 indicates the company holds enough short-term assets to cover its near-term obligations.
MITO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that executives believe in the value of their developments.
- Social sentiment has shifted positively as community discussions highlight the potential of Stealth BioTherapeutics' innovative therapies targeting mitochondrial diseases.
- Recent announcements about upcoming clinical trial results have generated excitement, with many investors optimistic about the potential breakthroughs.
- The overall biotech sector has seen a resurgence, which can create a favorable environment for companies like Stealth BioTherapeutics to gain traction.
Bear Case
- Concerns about the company's cash runway have been raised, with some investors worried about funding sustainability for ongoing research and development.
- Negative sentiment has emerged from discussions around regulatory hurdles that could delay product approvals and impact market entry.
- Some community members express skepticism about the company's ability to deliver on its ambitious timelines, citing previous delays in clinical trials.
- Market volatility in the biotech sector can lead to heightened risks, with many investors cautious about investing in companies with uncertain outcomes.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MITO Latest News
No recent news available for MITO.
Leadership: Irene P. McCarthy
Managing Director
Irene P. McCarthy serves as Managing Director at Stealth BioTherapeutics, overseeing the company's operations and strategic direction. Her background includes experience in the biotechnology and pharmaceutical industries, with a focus on clinical development and regulatory affairs. She is responsible for managing a team of 38 employees and guiding the company through critical clinical trial stages.
Track Record: Under Irene McCarthy's leadership, Stealth BioTherapeutics has advanced Elamipretide through multiple clinical trials, including Phase 3 studies for Barth syndrome and Replisome myopathies. She has also overseen the development of the company's pipeline of product candidates targeting various diseases involving mitochondrial dysfunction.
Stealth BioTherapeutics Corp ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. For Stealth BioTherapeutics (MITO), each ADR represents a specific number of shares in the company's home market, allowing U.S. investors to easily invest in the company without dealing with foreign exchanges.
- Home Market Ticker: Unknown
- ADR Level: 2
- ADR Ratio: 1:1
Stealth BioTherapeutics Corp Healthcare Stock: Key Questions Answered
What happened to Stealth BioTherapeutics Corp (MITO) stock?
Stealth BioTherapeutics Corp (MITO) no longer trades on public markets. It was delisted in November 2022. The figures below are historical and are not a current quote.
Can I still buy MITO shares?
No. MITO stopped trading on public markets in November 2022, so the shares are not available through a broker. Anything you see quoted for MITO elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before MITO stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Stealth BioTherapeutics Corp. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Stealth BioTherapeutics Corp do?
Stealth BioTherapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing therapies for diseases involving mitochondrial dysfunction. Their lead product candidate, Elamipretide, is currently in Phase 3 clinical trials for Barth syndrome and Replisome myopathies, as well as Phase 2/3 trials for Duchenne cardiomyopathy.
What do analysts say about MITO stock?
Analyst coverage for Stealth BioTherapeutics Corp is limited, reflecting its small market capitalization and clinical-stage status. Key valuation metrics are heavily influenced by the potential success of Elamipretide and other pipeline candidates. Growth considerations center on clinical trial results, regulatory approvals, and commercialization prospects. Due to the inherent risks in biotechnology, analyst opinions may vary widely. Investors should conduct their own due diligence and consider their risk tolerance before investing.
What are the main risks for MITO?
Stealth BioTherapeutics Corp faces significant risks inherent to the biotechnology industry. Clinical trial failures represent a major risk, as negative results could halt the development of Elamipretide and other pipeline candidates. Regulatory hurdles and delays in obtaining marketing approvals also pose a threat. Competition from other biotechnology companies developing therapies for similar indications could erode market share.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-18.
- AI analysis is pending and may provide further insights.